Abstract A026: An alternative to HER2 IHC 0/1+/2+ status to predict which clinically HER2-negative patients will respond to anti-HER2 therapies: A rationale for the likely superiority of quantitative HER2 pathway RPPA measurements
Julia Wulfkuhle(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Laura van ‘t Veer, Lajos Pusztai(Yale University), Paula R. Pohlmann(The University of Texas MD Anderson Cancer Center), Lamorna Brown Swigart(University of California, San Francisco), Amy L. Delson(Children's Advocacy Center), Rosa I. Gallagher(George Mason University), Christina Yau(Hospital Authority), Alexander D. Borowsky(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Angela DeMichele(University of Pennsylvania), Hope S. Rugo(City of Hope), Denise M. Wolf
Cited by 0
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k